152 related articles for article (PubMed ID: 6380788)
21. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
22. Comparative distribution and excretion of carboplatin and cisplatin in mice.
Siddik ZH; Jones M; Boxall FE; Harrap KR
Cancer Chemother Pharmacol; 1988; 21(1):19-24. PubMed ID: 3277732
[TBL] [Abstract][Full Text] [Related]
23. Treatment of human ovarian tumor xenografts with selenite prevents the melphalan-induced development of drug resistance.
Caffrey PB; Frenkel GD
Anticancer Res; 1998; 18(4C):3017-20. PubMed ID: 9713502
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.
Harland SJ; Newell DR; Siddik ZH; Chadwick R; Calvert AH; Harrap KR
Cancer Res; 1984 Apr; 44(4):1693-7. PubMed ID: 6367971
[TBL] [Abstract][Full Text] [Related]
25. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.
Mistry P; Kelland LR; Abel G; Sidhar S; Harrap KR
Br J Cancer; 1991 Aug; 64(2):215-20. PubMed ID: 1892748
[TBL] [Abstract][Full Text] [Related]
26. Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines.
Perez RP; O'Dwyer PJ; Handel LM; Ozols RF; Hamilton TC
Int J Cancer; 1991 May; 48(2):265-9. PubMed ID: 2019469
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of cis-platin and carboplatin in the chemotherapy of squamous cell carcinoma grown as multicellular spheroids.
Schwachöfer JH; Crooijmans RP; Hoogenhout J; Kal HB; Theeuwes AG
Anticancer Res; 1990; 10(3):805-11. PubMed ID: 2195988
[TBL] [Abstract][Full Text] [Related]
28. Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.
Sharp SY; Mistry P; Valenti MR; Bryant AP; Kelland LR
Cancer Chemother Pharmacol; 1994; 35(2):137-43. PubMed ID: 7987990
[TBL] [Abstract][Full Text] [Related]
29. Modulation of melphalan and cisplatin cytotoxicity in human ovarian cancer cells resistant to alkylating drugs.
Gornati D; Zaffaroni N; Villa R; De Marco C; Silvestrini R
Anticancer Drugs; 1997 Jun; 8(5):509-16. PubMed ID: 9215615
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma.
Evans BD; Raju KS; Calvert AH; Harland SJ; Wiltshaw E
Cancer Treat Rep; 1983 Nov; 67(11):997-1000. PubMed ID: 6315233
[TBL] [Abstract][Full Text] [Related]
31. In vitro cytotoxic drug sensitivity testing of human tumour xenografts grown as multicellular tumour spheroids.
Jones AC; Stratford IJ; Wilson PA; Peckham MJ
Br J Cancer; 1982 Dec; 46(6):870-9. PubMed ID: 6891260
[TBL] [Abstract][Full Text] [Related]
32. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
Boven E; Verschraagen M; Hulscher TM; Erkelens CA; Hausheer FH; Pinedo HM; van der Vijgh WJ
Eur J Cancer; 2002 May; 38(8):1148-56. PubMed ID: 12008205
[TBL] [Abstract][Full Text] [Related]
33. An in vitro study comparing the cytotoxicity of three platinum complexes with regard to the effect of thiol depletion.
Smith E; Brock AP
Br J Cancer; 1988 Jun; 57(6):548-52. PubMed ID: 3044430
[TBL] [Abstract][Full Text] [Related]
34. Resistance and cross-resistance of the IgM immunocytoma in the LOU/M Wsl rat for cisplatin, carboplatin, and iproplatin.
Steerenberg PA; Vendrik CP; de Jong WH; de Groot G; Fichtinger-Schepman AM; Scheefhals AP; Schornagel JH
Cancer Chemother Pharmacol; 1988; 22(1):51-7. PubMed ID: 3293840
[TBL] [Abstract][Full Text] [Related]
35. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.
Calvert AH; Harland SJ; Newell DR; Siddik ZH; Jones AC; McElwain TJ; Raju S; Wiltshaw E; Smith IE; Baker JM; Peckham MJ; Harrap KR
Cancer Chemother Pharmacol; 1982; 9(3):140-7. PubMed ID: 6761010
[TBL] [Abstract][Full Text] [Related]
36. Hyperthermic enhancement of cell killing by five platinum complexes in human malignant melanoma cells grown as monolayer cultures and multicellular spheroids.
Kubota N; Kakehi M; Inada T
Int J Radiat Oncol Biol Phys; 1993 Feb; 25(3):491-7. PubMed ID: 8436528
[TBL] [Abstract][Full Text] [Related]
37. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.
Perego P; Gatti L; Righetti SC; Beretta GL; Carenini N; Corna E; Dal Bo L; Tinelli S; Colangelo D; Leone R; Apostoli P; Lombardi L; Beggiolin G; Piazzoni L; Zunino F
Int J Cancer; 2003 Jul; 105(5):617-24. PubMed ID: 12740909
[TBL] [Abstract][Full Text] [Related]
38. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
39. Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts.
Boven E; van der Vijgh WJ; Nauta MM; Schlüper HM; Pinedo HM
Cancer Res; 1985 Jan; 45(1):86-90. PubMed ID: 4038381
[TBL] [Abstract][Full Text] [Related]
40. The relative effectiveness of analogues of cisplatin in the experimental chemotherapy of human non-small-cell lung cancer and neuroblastoma grown as multicellular spheroids.
Russell J; Adam J; Wheldon TE; Kaye SB
Cancer Chemother Pharmacol; 1989; 23(2):111-4. PubMed ID: 2535968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
